(NASDAQ: MYGN) Myriad Genetics's forecast annual revenue growth rate of 5.42% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.82%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.18%.
Myriad Genetics's revenue in 2026 is $825,300,000.On average, 15 Wall Street analysts forecast MYGN's revenue for 2026 to be $82,446,604,972, with the lowest MYGN revenue forecast at $76,285,177,948, and the highest MYGN revenue forecast at $87,725,298,049. On average, 14 Wall Street analysts forecast MYGN's revenue for 2027 to be $86,781,975,182, with the lowest MYGN revenue forecast at $78,032,003,098, and the highest MYGN revenue forecast at $93,586,576,888.
In 2028, MYGN is forecast to generate $89,644,568,585 in revenue, with the lowest revenue forecast at $82,762,599,489 and the highest revenue forecast at $95,077,996,440.